Modification of the cytotoxic activity of mitomycin C.
Read Online

Modification of the cytotoxic activity of mitomycin C. by Raymond Stewart Marshall

  • 945 Want to read
  • ·
  • 29 Currently reading

Published .
Written in English

Book details:

The Physical Object
Pagination109 leaves
Number of Pages109
ID Numbers
Open LibraryOL18882377M

Download Modification of the cytotoxic activity of mitomycin C.


  Mitomycin C (0–10 μ m) or vehicle control was added in a 1-μl volume to the reaction tube immediately prior to the addition of 1 μl messenger RNA-encoding firefly luciferase, which served as the translation template (luciferase control mRNA, 1 μg/μl, Promega). The reaction was allowed to proceed for 90 min at 30 degrees, as per the. The effectiveness of valproic acid was greatly enhanced in human bladder cancer cells, when it was combined with the DNA-damaging agent mitomycin C, likely due to the augmented cytotoxic activity. Conclusion The cytotoxicity of mitomycin C was greater under acidic conditions for all these cell lines confirming that the activity of mitomycin C depends on pH and suggesting that the pH of the vehicle used for intravesical chemotherapy may be an important factor in the successful treatment of bladder carcinomas. The modification of pH by Cited by: 4. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant. Cancer Res – CAS.

The molecular mechanism of differentiation interruption by mitomycin C in the Non-small-cell lung cancer (NSCLC) line A was investigated. High dosage of mitomycin C ( µM) could significantly inhibit cell proliferation (P. ) by ± % (P. ), under which cell . MITOMYCIN-C KYOWA® NAME OF DRUG MITOMYCIN-C KYOWA® (mitomycin C). (BAN, USAN, INN) DESCRIPTION MITOMYCIN-C KYOWA ® is an antibiotic isolated from the broth of Streptomyces caespitosus which has been shown to have anti-tumour activity. Mitomycin C is a blue-purple crystalline powder slightly soluble in water or ethanol and insoluble in ether. Mitomycin for Injection is a sterile dry mixture of mitomycin and mannitol, which, when reconstituted with Sterile Water for Injection, provides a solution for intravenous administration. Each vial contains either mitomycin 5 mg and mannitol 10 mg, or mitomycin 20 mg and mannitol 40 mg, or mitomycin 40 mg and mannitol 80 mg. C15H18N4O5 M.W. Mitomycin-C and MTC are other names for Mitomycin. In some cases, health care professionals may use the trade name Mutamycin or other names Mitomycin-C and MTC when referring to the generic drug name Mitomycin. Drug type: Mitomycin-C is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as an.

  Abstract. Purpose: Mitomycin C (MMC) is widely used in treatment of non-muscle invasive bladder cancer at a 1 mg/mL concentration, by intravesical is also used as an ophthalmic procedure in glaucoma care mostly with mg/mL concentration. To accelerate syringes provision, it could be interesting to demonstrate the stability of the drug, in order to be able to prepare . Summary. The effects of mitomycin C (MMC) on the generation of cell-mediated cytotoxicity in primary stimulation culture of human peripheral blood mononuclear cells (PBM) with the B lymphoblastoid Raji cell line were assessed.   Self-protection in the mitomycin C (MC)-producing microorganism Streptomyces lavendulae includes MRD, a protein that binds MC in the presence of NADH and functions as a component of a unique drug binding-export system. Characterization of MRD revealed that it reductively transforms MC into 1,2- cis hydroxy-2,7-diaminomitosene, a compound that is produced in the . Mitomycin C (MMC) is a powerful anti-bacterial, anti-fungal and anti-tumor antibiotic, often active against multidrug resistant cells. Despite a broad spectrum of antitumor activity, MMC clinical use is relatively limited due to its fast clearance and dose-limiting toxicity.